Dr. Ilya Kleyn, CMO

Dr. Kleyn currently serves as Noigel’s Chief Medical Officer. Dr. Kleyn has been a physician since 1996, serving at some of New York’s premier hospitals including Mount Sinai and New York Presbyterian. He also oversees a multi-site group family and geriatric medical practice, leading to his strong relationship with a number of Atria assisted living centers, where he provides care to residents.

In addition to his considerable clinical background, Dr. Kleyn has served as Principal Investigator on many important studies for companies including Boeringer-Ingelheim, Pfizer, and Bio-delivery Sciences. He has performed research in a variety of areas and helped bring new treatments to the public. His research interests are primarily in infectious disease and Internal Medicine field (Diabetes, Hypertension, Hyperlipidemia, etc.), but he is open to collaborating on other research opportunities andany treatment which will help his patients.

While at NOIGEL, Dr. Kleyn has successfully led several important company posters, conferences and presentations. In 2016 he participated at SMI Global Annual Conference Superbugs & Superdrugs and in 2017 presented at the BIO CEO and Investor conference. He has spearheaded their entrance to the U.S. market.

Research Experience 
Principal Investigator:
Clinical Trial Name and Protocol Number (the “Clinical Trial”):
VX14-787-103:       A Phase 2b,
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,
Multicenter Study of 2 Dose Levels of VX-787 Administered as
Monotherapy and One Dose Level of VX-787 Administered in Combination
With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal
Influenza A in Adult Subjects, 2014

Principal Investigator:
Sponsor: Boeringer-Ingelheim . A randomised, double-blind,
placebo-controlled, parallel group, efficacy and safety study of
empagliflozin (10 mg, 25 mg) administered orally, once daily over 24
weeks in hypertensive black/African American patients with type 2
diabetes mellitus, 2014.

Principal Investigator:
PrecisionMed Protocol 8009 SAMPLE Registry
Serial Alzheimer’s disease and MCI Prospective Longitudinal Evaluation, 2013

Principal Investigator:

Principal Investigator:
SPONSOR: SeraTrials, A Bioreclamation Company
PROTOCOL NO: 05035 PROTOCOL TITLE: Prospective Collection of Samples for Research
Studies with this sponsor for following indications:
Asthma, COPD, Hepatitis C, HIV, Diabetes

Principal Investigator:
SPONSOR: SeraTrials, A Bioreclamation Company
A study to collect nasal or throat swabs for patients exhibiting flu-like symptoms, 2014.